INTRODUCTION

As the most severe and fatal complication of ischemic heart disease, myocardial infarction (MI) causes 7.4 million deaths globally each year [1]. MI is characterized by decreased coronary blood flow which causes insufficient oxygen supply to cardiac tissue [2]. The resulting cardiac ischemia leads to mitochondrial malfunction, activation of the ischemic cascade, and cell death [3]. Treatments of the disease include early intervention by oxygen supplementation, use of anticoagulants, and immediate reperfusion [2, 3]. With the current available treatments, however, the prognosis of MI is still poor. It is therefore necessary to investigate the underlying mechanism of MI, which may help improve the understanding of the disease and potentially indicate new therapeutic targets.

Pyroptosis is a new type of programmed cell death that is characterized by the formation of membrane pores and cell lysis [4]. Pyroptosis is driven by caspase-1 or caspase-4/5/11 and has been implicated in many types of cardiovascular diseases [5]. The nucleotide oligomerization domain (NOD)-like receptor protein 3 (NLRP3) inflammasome plays essential roles in MI. NLRP3 induces cardiomyocyte pyroptosis by activating caspase-1, followed by cleavage of gasdermin D (GSDMD) and release of proinflammatory cytokines (interleukin-1β and interleukin-18) [5–9]. Some studies found that increased generation of reactive oxygen species (ROS) in mitochondrial dysfunction induced the assembly of NLRP3 and ASC at mitochondria and subsequent activation of NLRP3 [10, 11]. However, the exact role of pyroptosis in MI remains unclear.
A member of Hypoxia inducible Factor 1 (HIF-1) family, HIF-1α, was found to exert cardioprotective functions in MI [12]. However, some studies showed opposing results that HIF-1α also plays harmful roles in myocardial injuries [13–15]. Mitochondrial dysfunction was reported to decrease HIF-1α signalling in hypoxia [16], and inhibiting activation of HIF-1α prevents mitochondrial dysfunction in hepatic ischemia-reperfusion (I/R) injury [17]. Hypoxia-induced ROS activate pyroptosis of myoblasts through the HIF-1α signalling pathway [18]. These findings are, however, still quite limited, and more investigations are needed to further elucidate the relationship between HIF-1α, pyroptosis, and mitochondrial dysfunction in MI.

Long noncoding RNAs (lncRNAs) play key roles in many biological and pathological processes by binding to their regulators on chromosomes [19]. Several lncRNAs were found to be involved in myocardial I/R injury, e.g., HULC, SNHG8, UCA1, NEAT1, and TUG1 [20–23]. LncRNA-TUG1 (taurine-upregulated 1) has been well studied in cancer [24]. Previous studies by our group and other investigators suggested that TUG1 also contributed to I/R injury in MI [23, 25–27]. Our preliminary bioinformatics analysis using JASPAR (http://jaspar.genereg.net/) found a binding site of HIF-1α on the promoter region of TUG1.

Using in vitro and in vivo MI models, our results showed for the first time that HIF-1α positively regulates TUG1 expression by binding to its promoter region, which contributes to hypoxia-induced myocardial injury in MI by promoting mitochondrial dysfunction and cardiomyocyte pyroptosis. Silencing of the HIF-1α/TUG1 pathway may be used as a potential treatment target to alleviate myocardial injury in MI.

RESULTS
Mitochondrial dysfunction and pyroptosis were induced in H/R-treated cardiomyocytes

We first generated in vitro hypoxic cell models by treating a mouse cardiomyocyte cell line (HL-1) and primary mouse cardiomyocytes with H/R. After H/R treatment, the proliferation ability of the cardiomyocytes was damaged (Fig. 1A), and ROS levels and lactate dehydrogenase (LDH) leakage were increased (Fig. 1B, C). JC-1 staining results showed decreased mitochondrial membrane potential (Fig. 1D, E), which indicated mitochondrial dysfunction induced by H/R treatment in cardiomyocytes. The results showed that the mRNA expression of IL-1β and IL-18 was elevated after H/R treatment (Fig. 1F, G), and Western blot analysis showed increased levels of pyroptosis-related proteins, including NLRP3, Caspase-1, ASC, GSDMD, and cleaved caspase-1, and GSDMD-N (cleaved GSDMD) (Fig. 1H, I). All these results indicated that H/R treatment induced pyroptosis in HL-1 cells and primary cardiomyocytes through activation of NLRP3 signalling.

TUG1 expression was increased by HIF-1α in cardiomyocytes by binding to its promoter region

Considering the potential role of HIF-1α and TUG1 in MI, we measured their expression in the H/R-treated cell models and found that the expression levels of those two factors were elevated after H/R treatment (Fig. 2A, B). After successful transfection of vector expressing HIF-1α or expressing shRNA targeting HIF-1α in both HL-1 and primary cardiomyocytes (Fig. 2C–E), the expression level of TUG1 was increased in the HIF-1α overexpression model and decreased in the HIF-1α-silenced model (Fig. 2F). Luciferase reporter assay results showed that the activity of TUG1 was enhanced when HIF-1α was overexpressed and inhibited when HIF-1α expression was silenced in cardiomyocyte models (Fig. 2G). In the chromatin immunoprecipitation (ChIP) assay, the HIF-1α antibody successfully pulled down TUG1 (Fig. 2H) in cardiomyocyte, indicating direct binding of the two factors. These results indicate that HIF-1α is an upstream regulator of TUG1 and that HIF-1α directly promotes TUG1 expression.

H/R treatment-induced mitochondrial dysfunction and pyroptosis were inhibited by silencing TUG1 in cardiomyocytes

After silencing TUG1 expression (Fig. 3A), both HL-1 and primary mouse cardiomyocytes showed decreased ROS levels and increased mitochondrial membrane potential when they received H/R treatment (Fig. 3B–D). TUG1 silencing also inhibited the activation of pyroptosis by H/R treatment (Fig. 3E, F). Additionally, TUG1 silencing also inhibited the increase in IL-1β and IL-18 levels induced by H/R treatment (Fig. 3G, H) and the activation of pyroptosis-related proteins (Fig. 3I, J). These results further confirm that TUG1 plays key roles in H/R-induced mitochondrial dysfunction and pyroptosis of cardiomyocytes.

TUG1 promotes FUS expression by directly binding to the protein

FUS (fused in sarcoma) was reported to be involved in cardiac repair after MI [29]. The results showed that the expression of FUS was increased in H/R-treated cardiomyocytes, and silencing TUG1 inhibited FUS expression (Fig. 4A). TUG1 was pulled down using FUS antibody, indicating direct binding between TUG1 and FUS protein (Fig. 4B). Separate Western blot analysis of the proteins in the cytoplasm, mitochondrial fraction and whole cell lysates showed that H/R treatment increased FUS protein levels both in the mitochondrial fraction and whole cell samples of cardiomyocytes, while silencing TUG1 inhibited the increase in FUS observed in H/R-treated cells, which did not result in significant changes in the cytoplasm (Fig. 4C). These observations were consistent with our preliminary bioinformatics analysis results and confirmed that FUS expression is regulated by TUG1 by direct binding.

The inhibitory effect of TUG1 silencing on H/R-induced mitochondrial dysfunction and pyroptosis was reversed by FUS overexpression in cardiomyocytes

After the generation of FUS overexpression or FUS-silenced models (Fig. 4D–F), we observed that FUS silencing inhibited the H/R-induced increase in ROS and decrease in mitochondrial membrane potential (Fig. 4G–I), as observed in TUG1 silencing. Furthermore, FUS overexpression reversed the inhibition of H/R-induced effects in TUG1-silenced cardiomyocyte models (Fig. 4G–I). We also investigated pyroptosis in our cardiomyocyte models and observed that similar to silencing TUG1, silencing FUS inhibited the H/R-induced activation of caspase-1 (Fig. 5A, B) and increased IL-1β and IL-18 expression and pyroptosis-related markers (Fig. 5C–F). Similarly, FUS overexpression also reversed the inhibition of H/R-induced changes in pyroptosis by TUG1 silencing in cardiomyocyte models (Fig. 5A–F). These results indicate that FUS is involved as the downstream signalling factor of TUG1 in H/R-induced mitochondrial dysfunction and pyroptosis in cardiomyocytes.

H/R-induced pyroptosis was inhibited by silencing TUG1 in cardiomyocytes through inhibition of ROS production

Several previous studies indicated that pyroptosis was inhibited by decreasing ROS levels [30–33]. Therefore, we also investigated the possible role of ROS in H/R-induced pyroptosis of cardiomyocytes. Using an ROS inhibitor, N-acetylcysteine (NAC), we observed inhibition of caspase-1 activation in H/R-treated cardiomyocytes (Fig. 6A, B). Additionally, treatment with NAC in TUG1-silenced cardiomyocytes led to even lower caspase-1 activity than treatment with NAC or TUG1 silencing alone (Fig. 6A, B). Similarly,
NAC inhibited the H/R-induced increase in IL-1β and IL-18 and the expression of pyroptosis-related proteins, including NLRP3, caspase-1, ASC, GSDMD, cleaved caspase-1, and cleaved GSDMD (Fig. 6C–F), and cotreatment with NAC in TUG1-silenced cardiomyocytes showed lower levels of those factors than NAC treatment or TUG1 silencing alone. These results indicate that ROS play key roles in promoting pyroptosis in H/R-treated cardiomyocytes.

I/R treatment-induced myocardial damage was reduced by silencing TUG1 in an in vivo mouse model

We then continued to validate our hypothesis in in vivo mouse models. TTC staining results indicated an increased MI area in the I/R group compared to the control group (sham), while silencing TUG1 reduced the MI area (Fig. 7A, B). H&E staining showed damaged cardiac structures and significant cell death in the I/R group, and the cardiac damage in the I/R + shTUG1 group was partially relieved.
compared to the I/R group (Fig. 7C). We also measured the serum markers for cardiac damage using ELISA, including serum LDH, creatine kinase (CK), and CK-MB. The results showed significantly elevated serum levels of these markers in I/R-treated mice (Fig. 7D–F). Further silencing of TUG1 significantly decreased the levels of cardiac damage markers, indicating protective effects. Similarly, TUNEL staining also showed increased cell death in cardiac tissue in I/R-treated mice, which was also inhibited by further silencing of TUG1 (Fig. 7G, H). These results show that silencing TUG1 reduces the cardiac damage caused by I/R in an in vivo model.

**FUS expression, mitochondrial dysfunction and pyroptosis were inhibited by silencing TUG1 in an in vivo mouse model**

Further qRT-PCR analysis of the expression levels of TUG1 and FUS showed increased expression of these two factors in cardiac tissue in I/R-treated mice (Fig. 8A, B). FUS protein levels were also increased in cardiac tissue of I/R-treated mice, as shown in immunohistochemistry staining results (Fig. 8C). Further silencing of TUG1 inhibited the expression of FUS at both the mRNA and protein levels (Fig. 8A–C), indicating that TUG1 regulated FUS expression in an in vivo model. Serum ROS levels were increased by I/R treatment (Fig. 8D), which was inhibited by further silencing of TUG1. Levels of IL-1β and IL-18 were also increased by I/R treatment (Fig. 8E, F), accompanied by increased protein levels of FUS and pyroptosis-related markers, including NLRP3, ASC, caspase-1, GSDMD, cleaved caspase-1, and cleaved GSDMD (Fig. 8G, H), which also was inhibited by further silencing of TUG1, indicating that TUG1 also regulates the expression of downstream inflammatory factors and pyroptosis of cardiomyocytes.

**DISCUSSION**

MI is the most severe and fatal complication of ischemic heart disease, which causes millions of deaths globally every year [1].
Fig. 3 Silencing TUG1 inhibited H/R treatment-induced mitochondrial dysfunction and pyroptosis in cardiomyocytes. A qRT-PCR measurement of TUG1 levels in cardiomyocytes transfected with shTUG1 or cshNC. HL-1 and primary mouse cardiomyocytes were transfected with shNC or shTUG1 and then treated with H/R. B ROS levels were measured using a DHE assay. C, D Mitochondrial membrane potential was evaluated using JC-1 staining. E, F Caspase-1 activity was measured using flow cytometry. G IL-1β and H IL-18 expression was measured using qRT-PCR. I, J The expression of pyroptosis-related markers was measured using western blotting. *P < 0.05, **P < 0.01 and ***P < 0.001.
Fig. 4 TUG1 promoted FUS expression by directly binding to the molecules, and overexpression of FUS reversed the effects of TUG1 silencing on H/R-induced mitochondrial dysfunction in cardiomyocytes. A qRT-PCR measurement of FUS levels in H/R-treated cardiomyocytes transfected with shTUG1 or shNC. B RIP assay on the presence of TUG1 in cardiomyocyte samples pulled down by anti-FUS antibody or control IgG. C Western blotting measurement of FUS expression in the cardiomyocytes cytoplasm, mitochondrial fraction. The D mRNA and E, F protein levels of FUS were measured using qRT-PCR and western blotting in cardiomyocytes transfected with shFUS, shNC, vector expressing FUS, or empty vector. G ROS levels were measured using a DHE assay. H, I Mitochondrial membrane potential was evaluated using JC-1 staining. *P < 0.05, **P < 0.01 and ***P < 0.001.
Fig. 5  Overexpression of FUS reversed the effects of TUG1 silencing on H/R-induced pyroptosis in cardiomyocytes. A, B Caspase-1 activity was measured using flow cytometry. C IL-1β and D IL-18 expression was measured using qRT-PCR. E, F The expression of NLRP3, ASC, and other downstream pyroptosis-related factors was measured using western blotting. \*P < 0.05, \**P < 0.01 and \***P < 0.001.
Fig. 6  Silencing TUG1 inhibited H/R-induced pyroptosis of cardiomyocytes by decreasing the generation of ROS. HL-1 and primary mouse cardiomyocytes were transfected with shTUG1 or treated with the ROS inhibitor NAC and then subjected to H/R. A, B Caspase-1 activity was measured using flow cytometry. C, D IL-1β, and D IL-18 expression was measured using qRT-PCR. E, F The expression of NLRP3, ASC, and other downstream pyroptosis-related factors was measured using western blotting. *P < 0.05, **P < 0.01 and ***P < 0.001.
Previous investigations suggested roles of pyroptosis and mitochondrial dysfunction in the pathogenesis of MI [5, 11], and HIF-1α and TUG1 were found to be involved in the process [12, 27]. However, the underlying pathway remains elusive for the roles of HIF-1α and TUG1 in MI. Our results showed that HIF-1α directly regulated TUG1 expression, which promoted pyroptosis and mitochondrial dysfunction of cardiomyocytes by binding to FUS and increasing its expression, and suppression of this pathway may help reduce the I/R-induced damage to heart tissue.

Although studies on HIF-1α in cardiovascular disease suggested a cardioprotective role [12], studies by Tang [13] and Shyu [14, 15] revealed that HIF-1α also contributed to I/R injury in MI. Our results showed that HIF-1α increased TUG1 expression through binding to its promoter region. A study by Cai [23] showed that TUG1 knockdown reduced hypoxia-reoxygenation-induced injury to cardiomyocytes via the miR-532-5p/Sox8 axis. Other studies by Li [25] and Yang [26] found that TUG1 overexpression promoted, while knockdown of TUG1 suppressed, apoptosis of cardiomyocytes. Our previous studies also suggested that silencing TUG1 expression reduced hypoxia-induced myocardial injury through regulation of ROS via the miR-132-3p/HDAC3 axis [27] or through regulation of autophagy [28]. Based on these findings, this study further showed that silencing TUG1 reduced hypoxia-induced myocardial injury by...
inhibiting mitochondrial dysfunction and pyroptosis. Additionally, a study found that lipopolysaccharide increased hypoxia/reoxygenation-induced injury to cardiomyocytes in a ROS-dependent manner [36]. Similarly, our results also suggested a role for ROS in promoting pyroptosis in cardiomyocytes. The results of those studies supported the roles of TUG1 in MI, possibly through mitochondrial dysfunction and pyroptosis mediated by increased ROS generation.

FUS, a DNA/RNA binding protein, has been intensively studied for its role in neurodegeneration, especially amyotrophic lateral sclerosis [37, 38]. Previous bioinformatics analysis found that FUS protein is one of the key proteins that regulate most of the differentially expressed genes in MI [39], and the binding between TUG1 and FUS was confirmed in our experimental results. In addition, a few studies reported possible roles of FUS in the pathogenesis of MI. Garikipati
found that circular RNA circFncd3b promoted cardiac repair after MI by inhibiting the FUS/VEGFR-A axis and apoptosis of cardiomyocytes [29]. A study by Wang reported that miR-200a regulated cardiomyocyte apoptosis by targeting FUS [40]. We found that FUS was involved in the HIF-1α/TUG1 signalling pathway, which contributed to mitochondrial dysfunction and cardiomyocyte pyroptosis in MI.

In conclusion, our study found that the HIF-1α/TUG1/FUS axis plays key roles in myocardial injury in MI by regulating mitochondrial dysfunction and cardiomyocyte pyroptosis, which potentially served as a treatment target for MI. Our study is the first to show that HIF-1α regulates TUG1 expression by directly binding to its promoter region, which may be the underlying mechanism of the detrimental roles of HIF-1α in MI.

MATERIALS AND METHODS

Cell culture and treatments
A mouse cardiomyocyte cell line (HL-1) was obtained from the American Type Culture Collection (ATCC, USA). Primary cardiomyocytes were collected from mice that were 1–4 days old. Briefly, mice were euthanized using carbon dioxide, and the heart was immediately collected, washed in D-Hanks solution (Gibco, USA) and minced using scissors. Minced heart tissue was digested using trypsin (prepared in D-Hanks solution, pH 7.4) at 37 °C for 20 min with gentle shaking every 2 min. Samples were then centrifuged at 1000 rpm for 5 min. The supernatant was discarded, and the cell pellet was washed with D-Hanks solution. Cells were resuspended in culture medium and transferred into flasks. The HL-1 cell line and isolated primary cardiomyocytes were cultured in DMEM/F12 culture medium (Gibco, USA) supplemented with 10% foetal bovine serum, 100 IU/ml penicillin, and 100 μg/ml streptomycin (Invitrogen, USA) in an incubator at 37 °C with 5% CO2 and 90% humidity. The cells were authenticated by STR profiling, and the cells were tested without contamination with mycoplasma. To mimic myocardial I/R injury in vitro, cardiomyocytes were subjected to hypoxia-reoxygenation (H/R) treatment. Briefly, the cells were oxygenated at 37 °C for 8 h. Then, the cells were returned to normal glucose-containing medium at 37 °C for 20 min with gentle shaking every 2 min. Samples were then centrifuged at 1000 rpm for 5 min. The supernatant was discarded, and the cell pellet was washed with D-Hanks solution. Cells were resuspended in culture medium and transferred into flasks. The HL-1 cell line and isolated primary cardiomyocytes were cultured in DMEM/F12 culture medium (Gibco, USA). The primary cardiomyocytes were obtained from GenePharma (Shanghai, China) and transfected into the vector carrying hHIF-1α (PerkinElmer, USA) with excitation at 500 nm and emission at 590 nm.

Determination of mitochondrial membrane potential
Mitochondrial membrane potential was determined using a commercial JC-1 mitochondrial membrane potential assay kit (ab113850, Abbcm, USA) following the manufacturer’s instructions. Briefly, cells were seeded at 1.5 × 10^4 cells per well in a dark 96-well plate and allowed to attach overnight. Cells were washed with 1x dilution buffer and incubated with 10 μg/ml JC-1 solution for 10 min at 37 °C in the dark. After washing the plate twice with 1x dilution buffer, the results were obtained under an Axio Imager A1 microscope (Carl Zeiss, Germany).

Measurement of lactate dehydrogenase leakage
Measurement of LDH leakage was performed using a commercial LDH assay kit (ab65393, Abbcm, USA). Briefly, 100-μL cells were seeded in a 96-well plate in triplicate. After incubation at 37 °C, the cells were centrifuged at 4 °C for 10 min, and the supernatant was transferred into a new 96-well plate. In each well, 100-μL LDH reaction mix was added, and the plate was incubated for 30 min at room temperature. The results were obtained using a microplate reader (Thermo Fisher Scientific, USA) with excitation at 450 nm and emission at 650 nm.

Flow cytometry
Pyroptosis of cardiomyocytes was evaluated by measuring caspase-1 using flow cytometry. Briefly, a commercial FAM-FLICA in vitro Caspase Detection Kit (ImmunoChemistry, USA) was used following the manufacturer’s instructions. Samples were mixed with FLICA and PI and incubated at 37 °C for 1 h in the dark. After washing twice with wash buffer, the cells were analysed with a flow cytometer (BD Biosciences, USA).

Chromatin immunoprecipitation
ChiP assays were performed using a SimpleChiP Enzymatic Chromatin IP Kit (#9003, Cell Signaling Technology, USA) following the manufacturer’s instructions. The protein-RNA interaction was first cross-linked using 1% formaldehyde. After cell lysis, chromatin was partially digested using micrococcal nuclease and sonication. The digested chromatin was then incubated with HIF-1α antibody (#36169, Cell Signaling Technology, USA) or acetyl-histone H3 antibody (#9649, Cell Signaling Technology, USA) overnight at 4 °C. After pulldown by ChiP-Grade Protein G Magnetic Beads (#9006, Cell Signaling Technology, USA), the immune complex was eluted from the beads, and DNA was purified. The presence of TUG1 was examined using quantitative real-time PCR (qRT-PCR) with the primer pair forwards 5′-GGCCACCCAGTGAAGAAGC-3′ and reverse 5′-AAGACACAGATATAAGGTGTA-3′ (GenePharma, Shanghai, China). Rabbit immunoglobulin G (IgG) (#8726, Cell Signaling Technology, USA) was used as a negative control. PCR products were then separated using gel electrophoresis.

Luciferase reporter assay
The JASPAR database (http://jaspar.genereg.net/) was used to predict the potential binding sequence of HIF-1α and the TUG1 promoter. Following the analysis results, the TUG1 promoter sequence where HIF-1α binds was cloned into the pGL3 vector (Promega, USA). The vector was transfected into HL-1 and primary cardiomyocytes using Lipofectamine 2000 (Thermo Fisher Scientific, USA), which were then cotransfected with adenovirus vector carrying HIF-1α, shNC, HIF-1α or empty vector following the manufacturer’s instructions. After transfection for 48 h, cells were harvested, and luciferase activities were detected by the Dual-Luciferase Reporter Assay Kit (Promega). The ratio of firefly activity to Renilla luciferase activity was subsequently determined.

RNA immunoprecipitation
RNA immunoprecipitation (RIP) was performed using a Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, USA). HL-1 and primary mouse cardiomyocytes were cultured in flasks until ~80% confluency. After washing with ice-cold PBS, the cells were scraped and harvested by centrifugation at 1500 rpm for 5 min at 4 °C. After lysis in complete RIP lysis buffer, the cell lysate was centrifuged at 14,000 rpm for 10 min at 4 °C, and the supernatant was transferred to a new tube containing RIP immunoprecipitation buffer and magnetic beads bound with antiFU antibody (ab245332, Abbcm, USA) or rabbit IgG (ab172730, Abbcm, USA). After incubation with gentle rotation overnight at 4 °C, the samples were placed on a magnetic separator (Grainer, USA), and the supernatant was discarded. The beads were washed six times with cold RIP Wash Buffer. Protein K buffer was added.
and the mixture was incubated at 55 °C for 30 min to digest the proteins. After purification of RNA, qRT-PCR was used to detect TUG1 in the samples.

Separation of mitochondrial proteins
The separation of mitochondrial proteins was performed using Mitochondrial Protein Isolation Buffer (#97063-126, WVR Life Science, USA) following the manufacturer’s instructions. Briefly, 1 × 10⁶ cells were resuspended in 400-μL Mitochondrial Protein Isolation Buffer and homogenized 20 times on ice. After centrifugation, supernatant containing cytosolic proteins was transferred into a new tube, and the remaining pellet was resuspended in 1 mL Mitochondrial Protein Isolation Buffer and centrifuged. The pellet containing mitochondrial proteins was resuspended in 40-μL Mitochondrial Protein Isolation Buffer and frozen for future analysis.

Construction of the in vivo I/R mouse model
An in vivo mouse MI model was constructed using 10-week-old male C57BL/6 mice as described previously [27]. In all, 4 groups of animals (8 mice per group, which were chosen based on our previous studies and pilot experiments) were used, including I/R-treated mice (I/R), I/R-treated mice transfected with shTUG1 (I/R + shTUG1), I/R-treated mice transfected with shNC (I/R + shNC), and control animals (sham). Animals were purchased from Shanghai SLAC Experiment Animal Co. (Shanghai, China), randomly allocated into the 4 groups and kept in an SPF-grade animal-holding facility with a 12-h light:dark cycle. To generate a TUG1-silenced animal model, the aorta and pulmonary arteries were briefly cross-clamped (for 20 sec), and an adenosine vector carrying shTUG1 or shNC was quickly injected into the aortic root within the time period. After 5 days of recovery, to generate the I/R mouse model, the left anterior descending artery of the animals was ligated for 1 h to induce ischemia in the heart tissue and then reopened to allow reperfusion for 24 h. Animals in the negative control group received sham operation instead. Based on pre-established criteria, animals that did not survive the above procedures were excluded from further analysis. Animals were then euthanized using carbon dioxide, and the heart was quickly collected and processed for sectioning and subsequent staining. The investigators who performed the experiments were blinded to the group allocation. All animal experiments and protocols were reviewed and approved by the Animal Care and Use Committee of Guilin Medical University.

TTC staining
Before TTC staining, the heart samples were first frozen and sliced into 1-mm-thick sections. The sections were then stained with 1% 2,3,5-triphenyltetrazolium chloride (TTC) solution (Sigma–Aldrich, USA) for 15 min at 37 °C. The stained slides were photographed under a light microscope (Leica Microsystems, USA) and analysed using ImageJ software. The percentage of MI area was calculated by the area of fluorescence (ECL) system (Beyotime, China), and ImageJ was used to analyse the density of bands.

H&E staining
For H&E staining, heart samples were first fixed in 10% formalin and embedded in paraffin. The sample blocks were sectioned into 4-μm-thick sections, deparaffinized in xylene, and rehydrated in 100%, 95%, and 80% ethanol. The slides were then stained with haematoxylin for 3 min and washed three times under deionized water for 30 s. After differentiation in 1% acid ethanol, slides were stained with 0.5% eosin for 30 s, dehydrated in ethanol and xylene, and sealed in mounting medium with coverslip. After drying overnight at room temperature, the slides were examined and photographed under a light microscope (Leica Microsystems, USA).

TUNEL staining
A TUNEL Apoptosis Detection Kit (FITC) was purchased from Sangon Biotech (#E607178, Shanghai, China), and TUNEL staining was performed following the manufacturer’s instructions. Sample sections were treated with Protein K working solution for 10 min at 37 °C. After incubation with the reaction mixture for 2 h at 37 °C, Blocking Reagent was added, and the samples were incubated for 30 min at room temperature. Samples were then incubated with biotin-conjugated anti-digoxin antibody and SABC-FITC. After counterstaining with diamidino-2-phenylindole (DAPI), slides were mounted with mounting medium and observed under a fluorescence microscope (Leica Microsystems, USA).

Immunohistochemistry
Sample blocks were first sectioned at 4-μm thickness, deparaffinized in xylene, and rehydrated in ethanol and deionized water. After heat-mediated antigen retrieval, slides were stained with antIFUS antibody (1:100, ab124923, Abcam, USA) overnight at 4 °C. The next day, the slides were washed with 1x PBS-T and stained with HRP-conjugated goat anti-rabbit secondary IgG (1:5000, Abcam, USA) for 1 h. After counterstaining using haematoxylin for 30 s, the slides were washed and stained with 3,3′-diaminobenzidine. The results were examined and photographed under a light microscope (Leica Microsystems, USA).

Measurement of serum LDH, creatine kinase, and CK-MB using ELISA
Enzyme-linked immunoassay (ELISA) kits for CK (ab155901, Abcam, USA), LDH (A020-2-2, Nanjing JianCheng, China), and CK-MB (E006-1-1, Nanjing JianCheng, China) were used to measure their serum levels in an in vivo MI mouse model following the manufacturer’s instructions.

Extraction of total RNA, reverse transcription, and qRT-PCR
Total RNA was extracted from cells or tissue samples using TRIzol reagent (Invitrogen, USA) following the manufacturer’s instructions. cDNA was synthesized by reverse transcription using a TaqMan MicroRNA Reverse Transcription kit (Invitrogen, USA). qRT-PCR was then performed on an Applied Biosystems 7500 Real Time PCR System (Thermo Fisher Scientific, USA) using a reaction mixture consisting of 10 μL SYBR-Green Universal qPCR Master Mix (Bio-Rad, USA). β-Actin was used as an internal reference for mRNA. Specific primers for qRT-PCR are listed below. IL-1β, forwards 5′-TGGACCTTCAGGAAGGAGCACCA-3′, reverse 5′-GGTACTCTGACGAGCCTGTTG-3′; IL-1β, forwards 5′-GAGACGCGTGTCTGAGGAT-3′, reverse 5′-TGTTCTACAGGAGGAGGTAG-3′; TGF, forwards 5′-GACGACGAGGAGGAGGTGAC-3′, reverse 5′-CACGCTGCGGAGGTGACCA-3′; β-actin, forwards 5′-CATTGTCGAGCAGGATGCC-3′, reverse 5′-TGCTGGAGGGTGAGGACTG-3′; GSDMD, forwards 5′-ACTCGAGGGACCTGCTGAGC-3′, reverse 5′-GACGCTGAGTGTCCGATAGC-3′; cleaved GSDMD, forwards 5′-AGTCTCTCCACAGCAAGCACGAC-3′, reverse 5′-GACGCTGACGTGTCGATAGC-3′; ASC, forwards 5′-CTTCAGGGGTGTCACTTCAGAGA-3′, reverse 5′-AGTCATGGATGCCATTCAGT-3′; caspase-1, forwards 5′-GACGCTGAGTGTCCGATAGC-3′, reverse 5′-GACGCTGACGTGTCGATAGC-3′; cleaved caspase-1, forwards 5′-GACGCTGAGTGTCCGATAGC-3′, reverse 5′-GACGCTGACGTGTCGATAGC-3′; cleaved NLRP3, forwards 5′-GACGCTGAGTGTCCGATAGC-3′, reverse 5′-GACGCTGACGTGTCGATAGC-3′; COX IV, forwards 5′-ACTCGAGGGACCTGCTGAGC-3′, reverse 5′-GACGCTGACGTGTCGATAGC-3′; GAPDH, forwards 5′-GAGACGCGTGTCTGAGGAT-3′, reverse 5′-TGTTCTACAGGAGGAGGTAG-3′; β-actin, forwards 5′-CATTGTCGAGCAGGATGCC-3′, reverse 5′-TGCTGGAGGGTGAGGACTG-3′.

Statistical analysis
All experiments were repeated at least three times, and the results are summarized as the mean ± standard deviation (SD). Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software, USA). All data were normally distributed, and variance was similar between the groups that were statistically compared. Student’s t-test was used for comparisons between two groups, while one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test was used for comparisons between multiple groups. The result was considered statistically significant if P < 0.05 (two-tailed).
REFERENCES

1. O’Sullivan KE, Breen EP, Gallagher HC, Buggy DJ, Hurley JP. Understanding STAT3 signaling in cardiac ischemia. Basic Res Cardiol. 2016;111:27.

2. Lu L, Liu M, Sun R, Zheng Y, Zhang P. Myocardial infarction: symptoms and treatments. Cell Biochem Biophys. 2015;72:865–7.

3. Mechanic OJ, Grossman SA. Acute Myocardial Infarction. StatPearls. Treasure Island (FL); 2020.

4. Russo HM, Rathkey J, Boyd-Tressler A, Katsnelson MA, Abbott DW, Dubyak GR. Active Rac1 induces plasma membrane pores that precede pyrototic lysis and are blocked by lanthanides. J Immunol. 2016;197:1353–67.

5. Jia C, Chen H, Zhang J, Zhou K, Zhuhe Y, Niu C, et al. Role of pyroptosis in cardiovascular diseases. Int Immunopharmacol. 2019;67:311–8.

6. Takahashi M. Cell-specific roles of NLRP3 inflammasome in myocardial infarction. J Cardiovasc Pharmacol. 2019;74:188–93.

7. Zhaoji Z, Guohua L, Shiyuan W, Zuo W. Role of pyroptosis in cardiovascular disease. Cell Prolif. 2019;52:e12563.

8. Rauf A, Shah M, Yellow DM, Davidson SM. Role of caspase 1 in ischemia/reperfusion injury of the myocardium. J Cardiovasc Pharmacol. 2019;74:194–200.

9. Takahashi M. Role of NLRP3 inflammasome in cardiac inflammation and remodelling after myocardial infarction. Biopharm Bull. 2019;42:518–23.

10. Yabal M, Calleja DJ, Simpson DS, Lawlor KE. Stressing out the mitochondria: mechanistic insights into NLRP3 inflammasome activation. J Leukoc Biol. 2019;105:377–99.

11. Davidson SM, Adamoeva A, Barile L, Cabrera-Fuentes HA, Lazou A, Pagliaro P, et al. Mitochondrial and myocardial-independent pathways of myocardial cell death during ischaemia and reperfusion injury. J Cell Mol Med. 2020;24:7975–806.

12. Tekin D, Dursun AD, Xi L. Hypoxia inducible factor 1 (HIF-1) and cardioprotection. Acta Pharmacol Sin. 2010;31:1085–94.

13. Tang WH, Wu S, Wong TM, Chung SK, Chung SS. Polyol pathway mediates iron-induced oxidative injury in ischemic-reperfused rat heart. Free Radic Biol Med. 2008;45:602–10.

14. Shyu KG, Lu MJ, Chang H, Sun HY, Wang BW, Kuan P. Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure. J Card Fail. 2005;11:152–9.

15. Shyu KG, Liu JY, Wang BW, Fang WJ, Chang H. Cardioprotect prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci. 2005;12:809–20.

16. Chowdhury A, Aich A, Jain G, Wozny K, Luchtenborg C, Hartmann M, et al. Defective mitochondrial cardiolipin remodeling dampens HIF-1alpha expression in hypoxia. Cell Rep. 2018;25:561–70.

17. Bellanti F, Mirabella L, Matarotta D, Lusuardi M, Tamborra R, Cinnella G, et al. Propofol but not sevoflurane prevents mitochondrial dysfunction and oxidative stress by limiting HIF-1alpha activation in hepatic ischemia/reperfusion injury. Free Radic Biol Med. 2016;96:323–33.

18. Yu LM, Zhang WH, Han XX, Li YY, Lu Y, Pan J, et al. Hypoxia-induced ROS contribute to myoblast pyroptosis during obstructive sleep apnea via the NF-kappaB/HIF-1alpha signaling pathway. Oxid Med Cell Longev. 2019;2019:4596368.

19. Liao J, He Q, Li M, Chen Y, Liu Y, Wang J. LncRNA MIAT: myocardial infarction associated and more. Gene. 2016;578:158–61.

20. Liang J, Li F, Li H, Wang R, Du M. Overexpression of IncRNA HULC attenuates myocardial ischemia/reperfusion injury in rat models and apoptosis of hypoxia/reoxygenation cardiomyocytes via targeting miR-377-5p through NLRP3/Caspase1/IL1beta signaling pathway inhibition. Immunol Invest. 2021;50:925–38.

21. Zhang Y, Bian Y. Long non-coding RNA SNHG8 plays a key role in myocardial infarction through affecting hypoxia-induced cardiomyocyte injury. Med Sci Monit. 2020;26:e924016.

22. Gidlof O, Bader K, Celik S, Grossi M, Nakagawa S, Hirose T, et al. Inhibition of the long non-coding RNA NEAT1 protects cardiomyocytes from hypoxia in vitro via decreased pri-miRNA processing. Cell Death Dis. 2020;11:677.

23. Cai X, Wang S, Hong L, Yu S, Li B, Zeng H, et al. LncRNA TUG1 knockdown protects cardiomyocytes against hypoxia/reoxygenation-induced injury via regulating miR-332-3p/Stat3 axis. J Cardiovasc Pharmacol. 2020;76:556–63.

24. Zhou H, Sun L, Wan F. Molecular mechanisms of TUG1 in the proliferation, apoptosis, migration and invasion of cancer cells. Oncol Lett. 2019;18:4393–402.

25. Li B, Wu Y. LncRNA TUG1 overexpression promotes apoptosis of cardiomyocytes and predicts poor prognosis of myocardial infarction. J Clin Pharm Ther. 2020;45:1452–6.
CONSENT FOR PUBLICATION
Not Applicable. This article does not contain any studies with human participants performed by any of the authors.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41420-022-00969-8.

Correspondence and requests for materials should be addressed to Qiang Su.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022